Gilead Sciences GILD Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $6.96B-12.2% | $7.93B+2.0% | $7.77B+9.7% | $7.08B+6.2% | $6.67B-11.9% | ||
| $1.45B-11.0% | $1.62B+3.5% | $1.57B+4.5% | $1.5B-2.5% | $1.54B-2.6% | ||
| $5.52B-12.5% | $6.3B+1.6% | $6.2B+11.1% | $5.58B+8.9% | $5.13B-14.4% | ||
| 79.2%-0.3pp | 79.5%-0.3pp | 79.8%+1.0pp | 78.8%+1.9pp | 76.9%-2.2pp | ||
| $1.45B-19.1% | $1.79B+32.2% | $1.36B-0.6% | $1.37B+8.5% | $1.26B-34.0% | ||
| $4.37B-26.4% | $5.94B+33.7% | $4.44B-3.6% | $4.61B+4.0% | $4.43B-13.4% | ||
| $2.59B+30.3% | $1.98B-40.4% | $3.33B+34.5% | $2.47B+10.6% | $2.24B-8.8% | ||
| 37.2%+12.1pp | 25%-17.8pp | 42.8%+7.9pp | 34.9%+1.4pp | 33.6%+1.2pp | ||
| $240M-5.9% | $255M-0.4% | $256M+0.8% | $254M-2.3% | $260M+4.4% | ||
| $235M-32.7% | $349M-38.7% | $569M+174% | $208M+163% | -$328M— | ||
| $2.58B+24.2% | $2.08B-42.9% | $3.64B+49.9% | $2.43B+47.3% | $1.65B-23.9% | ||
| $559M— | $0-100% | $589M+25.9% | $468M+40.1% | $334M-13.2% | ||
| $2.02B-7.4% | $2.18B-28.5% | $3.05B+55.7% | $1.96B+49.0% | $1.32B-26.2% | ||
| 29%+1.5pp | 27.5%-11.7pp | 39.3%+11.6pp | 27.7%+8.0pp | 19.7%-3.8pp | ||
| $1.61-7.5% | $1.74-28.4% | $2.43+55.8% | $1.56+50.0% | $1.04-26.8% | ||
| $1.63-7.4% | $1.76-28.5% | $2.46+56.7% | $1.57+48.1% | $1.06-25.4% | ||
| 1.3B-0.1% | 1.3B+0.1% | 1.3B-0.1% | 1.3B-0.3% | 1.3B+0.3% | ||
| 1.2B-0.2% | 1.2B+0.1% | 1.2B-0.2% | 1.2B-0.1% | 1.2B-0.1% | ||
| $107M-80.1% | $539M+217% | $170M+179% | $61M-75.9% | $253M— | ||
| $596M-0.2% | $597M+0.2% | $596M-0.3% | $598M-0.2% | $599M+0.2% | ||
| $179M— | —— | $659M+470% | -$178M+10.6% | -$199M+47.5% | ||
| $93M+3.3% | $90M0.0% | $90M-3.2% | $93M-4.1% | $97M+2.1% | ||
| -$67M+29.5% | -$95M— | —— | -$162M-54.3% | -$105M— | ||
| -$134M— | —— | $333M+14.0% | $292M+470% | -$79M-9.7% | ||
| -$702M— | —— | $811M+589% | -$166M+32.0% | -$244M-180% | ||
| -$29M+78.4% | -$134M-9.8% | -$122M+90.6% | -$1.3B-136% | -$552M— | ||
| $52M-57.7% | $123M-76.1% | $515M+194% | $175M-21.5% | $223M-1.3% | ||
| -$5M-114% | $36M-90.2% | $368M+554% | -$81M-575% | -$12M-108% | ||
| -$4.24B-236% | -$1.26B+15.2% | -$1.49B+5.0% | -$1.57B+54.3% | -$3.43B— | ||
| $1.77B+196% | -$1.84B-330% | -$427M+79.8% | -$2.12B-410% | -$415M-84.4% | ||
| $2.54B-23.5% | $3.33B-19.0% | $4.11B+397% | $827M-52.9% | $1.76B-40.9% | ||
| -$183M+31.5% | -$267M-200% | -$89M-170% | -$33M+63.7% | -$91M-54.2% | ||
| $17M+255% | -$11M— | —— | —— | $23M+166% | ||
| $419M+82.2% | $230M-47.1% | $435M-17.5% | $527M-27.8% | $730M+109% | ||
| $1.04B+4.6% | $994M-1.1% | $1.01B+1.1% | $994M-1.6% | $1.01B+3.8% | ||
| $525M-62.0% | $1.38B+412% | $270M-86.5% | $2B— | $0— | ||
| $109M-82.1% | $609M+265% | $167M+695% | $21M-92.3% | $273M+264% | ||
| $117M-42.9% | $205M+39.5% | $147M+37.4% | $107M+2.9% | $104M-29.3% | ||
| $166M+419% | $32M-67.0% | $97M+259% | $27M-89.3% | $252M+45.7% | ||
| $36M+56.5% | $23M+35.3% | $17M+13.3% | $15M— | $0— | ||
| -$179M-184% | -$63M+54.0% | -$137M-114% | -$64M+63.6% | -$176M-274% | ||
| $2.52B+641% | $340M+55.3% | $219M-25.8% | $295M— | $0— | ||
| $2.77B+34,475% | $8M-11.1% | $9M0.0% | $9M-99.5% | $1.76B+25,071% | ||
| $1.37B-13.4% | $1.58B+17.7% | $1.35B-9.7% | $1.49B+8.1% | $1.38B-16.0% | ||
| $6.96B-12.2% | $7.93B+2.0% | $7.77B+9.7% | $7.08B+6.2% | $6.67B-11.9% | ||
| $218M-5.2% | $230M0.0% | $230M+2.2% | $225M+7.7% | $209M-5.9% | ||
| $2.59B+30.3% | $1.98B-40.4% | $3.33B+34.5% | $2.47B+10.6% | $2.24B-8.8% | ||
| $2.68B+29.2% | $2.07B-39.3% | $3.42B+33.1% | $2.57B+10.0% | $2.33B-8.4% | ||
| $2.68B+29.2% | $2.07B-39.3% | $3.42B+33.1% | $2.57B+10.0% | $2.33B-8.4% | ||
| 38.5%+12.3pp | 26.2%-17.8pp | 44%+7.7pp | 36.2%+1.2pp | 35%+1.4pp | ||
| $2.59B+30.3% | $1.98B-40.4% | $3.33B+34.5% | $2.47B+10.6% | $2.24B-8.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
